Gain‐of‐Function Effects of N‐Terminal CEBPA Mutations in Acute Myeloid Leukemia

Abstract excerpt

Mutations in the CEBPA gene are present in 10-15% of acute myeloid leukemia (AML) patients. The most frequent type of mutations leads to the expression of an N-terminally truncated variant of the transcription factor CCAAT/enhancer-binding protein alpha (C/EBPα), termed p30. While initial reports proposed that p30 represents a dominant-negative version of the wild-type C/EBPα protein, other studies show that p30...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Histone Deacetylase Inhibitors Research
• Share to Protein Degradation and Inhibitors